join fridays semaglutide Compounded (GLP-1) Join Fridays REVIEW for Telehealth

Recently, the GIP/GLP-1R co-agonist tirzepatide has gone through several randomized controlled trials and was approved by the FDA for T2DM and obesity in 2022 and 2023, respectively

[1] Managing Increased Urination While Taking GLP-1 Medications If you are experiencing increased urination whilst taking GLP-1 medication, several practical strategies can help manage this symptom whilst ensuring your treatment remains effective: Monitor your fluid intake : Maintain adequate hydration (NHS recommends 6-8 cups or glasses of fluid per day for most adults) but avoid excessive fluid consumption unless medically advised

for a 300-pound patient up to five times the average weight loss seen with traditional diet and exercise plans

Here's what the FDA reclassification means for peptide researchers

If your provider believes you would benefit from GLP-1 therapy, compounded semaglutide is the accessible option